Beacon Rise Holdings PLC
11 August 2026
The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation
11 August 2026
Beacon Rise Holdings Plc
("Beacon Rise" or the "Company")
Update in relation to the Proposed Ergotec Acquisition
On 29 September 2025 Beacon Rise (LSE: BRS) announced that it had entered non-binding heads of terms save for exclusivity and other customary terms in relation to the proposed acquisition of Ergotec Health LLP ("Ergotec Health") by the Company for a consideration of approximately £0.95 million (the "Proposed Ergotec Acquisition").
Following careful consideration, relating to key commercial terms, the board of directors of Beacon Rise (the "Board" or the "Directors") have concluded that it would not be in the best interest of the Company's shareholders to pursue the Proposed Ergotec Acquisition. Accordingly, the Board has terminated discussions in relation to the Proposed Ergotec Acquisition.
As noted in previous announcements, the Company intends to proceed with Cancellation and Admission should a final binding acquisition agreement be agreed in relation to at least one of the proposed acquisitions. Accordingly, the Board remains committed to finalising due diligence in relation to the previously announced Proposed Chiropractor Acquisition as well as the necessary transaction documentation in relation to Admission.
The Board intends to create an integrated physical healthcare services provider that is expected to provide physiotherapy, chiropractic and sports rehabilitation services to patients in the United Kingdom. The Board intends to achieve this primarily through implementing a structured buy-and-build strategy with the Proposed Chiropractor Acquisition representing the beginning of this strategy. With this in mind, the Board intends to explore other related potential acquisitions post-Admission, instead of seeking Admission contemporaneously with the completion of several related acquisitions. The Board also intends to supplement its growth strategy through pursuing relevant organic growth opportunities, where applicable.
Temporary suspension of listing and trading of Ordinary Shares
The Proposed Chiropractor Acquisition is classified as an "initial transaction" under UK Listing Rules ("UKLR") 13.4. In accordance with UKLR 21.1.4 and 21.3, the Company ordinary shares of £0.0001 each (ISIN: GB00BMC0V753) will remain suspended from its listing on the equity shares (shell companies) category of the Official List of the FCA and from trading on the Main Market of the London Stock Exchange.
Should final terms for the Proposed Chiropractor Acquisition be agreed, the Company will issue an announcement with further details pursuant to UKLR 13.4.22R and UKLR 13.4.23R.
There can be no certainty that the Proposed Chiropractor Acquisition will successfully complete, nor as to the final terms or timing of the Proposed Chiropractor Acquisition. If the Proposed Chiropractor Acquisition does not complete for any reason, it is expected that the suspension of the Company's listing on the Official List will be lifted, subject to FCA approval, and trading in the Company's shares on the Main Market of the London Stock Exchange will recommence.
The Company will release further announcements as and when appropriate.
Unless otherwise defined, definitions contained in this announcement have the same meaning as set out in the Company's notification on 29 September 2025 at 8:11 a.m.
Enquiries:
|
Beacon Rise Holdings Plc Xiaobing Wang, Chief Executive Officer & Director |
|
|
Allenby Capital Limited - Sponsor and Financial Adviser John Depasquale / Vivek Bhardwaj / Ashur Joseph |
Tel: +44 (0)20 3328 5656 info@allenbycapital.com |
|
LDC Nominee Secretary Limited - Company Secretary |
beaconrisecss@lawdeb.com |
|
Legal Entity Identifier (LEI) |
2138007PIYMZMBWD4M27 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.